Last reviewed · How we verify
recombinant human erythropoietin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
recombinant human erythropoietin (recombinant human erythropoietin) — University of Aarhus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant human erythropoietin TARGET | recombinant human erythropoietin | University of Aarhus | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant human erythropoietin CI watch — RSS
- recombinant human erythropoietin CI watch — Atom
- recombinant human erythropoietin CI watch — JSON
- recombinant human erythropoietin alone — RSS
Cite this brief
Drug Landscape (2026). recombinant human erythropoietin — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-erythropoietin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab